AXSM Q2 2025 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$150M+72.1% YoY

Gross Profit

$137M91.0% margin

Operating Income

-$37M-24.5% margin

Net Income

-$48M-32.0% margin

EPS (Diluted)

$-0.97

QoQ Revenue Growth

+23.5%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$640M

Total Liabilities

$567M

Stockholders' Equity

$73M

Cash & Equivalents

$303M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$150M	$87M	+72.1%
Gross Profit	$137M	$79M	+72.7%
Operating Income	-$37M	-$78M	+53.0%
Net Income	-$48M	-$79M	+39.5%

Revenue Segments

Product

$149M99%

Royalty

$1M1%

Geographic Segments

UNITED STATES

$146M98%

Non-US

$3M2%